Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 6.1%

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) shares fell 6.1% on Thursday . The company traded as low as $26.10 and last traded at $26.21. 435,006 shares traded hands during trading, a decline of 5% from the average session volume of 457,692 shares. The stock had previously closed at $27.91.

Analyst Upgrades and Downgrades

ARCT has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Arcturus Therapeutics in a research note on Wednesday, March 20th. William Blair reaffirmed an “outperform” rating on shares of Arcturus Therapeutics in a report on Friday, March 8th. Finally, Citigroup increased their price target on Arcturus Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a research note on Thursday, February 8th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $61.33.

Arcturus Therapeutics Price Performance

The company has a 50-day moving average price of $32.74 and a two-hundred day moving average price of $29.91.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Thursday, March 7th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.69) by $1.37. Arcturus Therapeutics had a negative return on equity of 18.22% and a negative net margin of 15.65%. The business had revenue of $33.99 million during the quarter, compared to the consensus estimate of $64.14 million. On average, research analysts predict that Arcturus Therapeutics Holdings Inc. will post -2.83 earnings per share for the current year.

Insider Activity at Arcturus Therapeutics

In other news, COO Pad Chivukula sold 17,435 shares of the firm’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $35.02, for a total value of $610,573.70. Following the completion of the sale, the chief operating officer now directly owns 473,448 shares in the company, valued at approximately $16,580,148.96. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 13.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ARCT. New York State Teachers Retirement System acquired a new position in shares of Arcturus Therapeutics during the third quarter worth approximately $53,000. AJOVista LLC bought a new stake in Arcturus Therapeutics during the 4th quarter valued at $65,000. Quest Partners LLC acquired a new position in Arcturus Therapeutics during the fourth quarter worth $67,000. Public Employees Retirement System of Ohio bought a new position in shares of Arcturus Therapeutics in the fourth quarter valued at $89,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Arcturus Therapeutics by 352.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,089 shares of the biotechnology company’s stock valued at $97,000 after buying an additional 2,406 shares during the last quarter. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.